Sanofi
Search results
22 hours ago · Boehringer Ingelheim produces its own green energy. Ingelheim, Germany, Mon, 07/08/2024 - 18:50. German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plant. Ingelheim site can cover 95% of its energy needs from renewable sources. New power plant helps achieve the company’s global climate targets ...
22 hours ago · With the new plant, the company expects to save around 50,000 tons of CO 2. It says the plant reduces the CO 2 emissions of the site’s own energy generation by 70%. In total, Boehringer Ingelheim plans to invest €205 million (nearly $222 million) in sustainable infrastructure projects at the Ingelheim site. It expects to cover 95% of its ...
5 days ago · Boehringer Ingelheim is further strengthening its comprehensive immuno-oncology pipeline with the progression of this program to accelerate next-generation cancer therapies to address high...
5 days ago · Anti-SIRPa monoclonal antibody licensed to Boehringer Ingelheim and is being developed in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination.
5 days ago · Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa cancer immunology treatment BI 770371
4 days ago · At Boehringer Ingelheim we develop breakthrough therapies that improve the lives of both humans and animals. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Now, we are powered by 52,000 employees globally who nurture a diverse, collaborative and inclusive culture.
22 hours ago · ASERVO EQUIHALER is a novel glucocorticoid (ciclesonide) delivered via Soft Mist™ inhaler indicated for the management of clinical signs associated with severe equine asthma in horses. For more information about Aservo EquiHaler please visit AservoEquihaler.com. Features & Benefits. Dosage & Administration.
